ImageneBio IMA
NASDAQ IMA
$4.05 -0.04 (-0.98%)
At close: Oct 22, 2026 · 4:00 PM EDT

ImageneBio (IMA) Asset Writedowns and Impairment (2024)

Updated

ImageneBio (IMA) reported Asset Writedowns and Impairment of $742,000 for FY2024, down 57.5% from $1.74 million in FY2023.

Analysis

ImageneBio (IMA) Asset Writedowns and Impairment (2024) Analysis & Trends

  • According to Business Quant data, Asset Writedowns and Impairment came in at $1.74 million in FY2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,139.85 Bn 1,108.44 Bn 19.71 Bn
2 Johnson & Johnson 634.68 Bn 554.54 Bn 17.30 Bn
3 AbbVie 500.89 Bn 474.00 Bn 12.70 Bn
4 Merck 354.57 Bn 308.95 Bn 12.21 Bn
5 Novartis Ag 300.14 Bn 264.13 Bn 11.24 Bn
6 Astrazeneca 263.08 Bn 236.77 Bn 12.86 Bn
7 Amgen 237.91 Bn 193.31 Bn 7.24 Bn
8 Gilead Sciences 193.96 Bn 168.15 Bn 6.22 Bn
9 Pfizer 170.07 Bn 116.71 Bn 10.94 Bn
10 ImageneBio 34.53 Mn -453.09 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2024 742,000.00
API Access

ImageneBio Asset Writedowns and Impairment API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=asset-writedowns-and-impairment&ticker=IMA&period=max&api_key=YOUR_API_KEY